Regeneron Reports First Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regeneron (REGN) Misses Q1 EPS by 101c, Revenues Miss; Provides FY19 Operating Outlook
May 7, 2019 6:36 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $4.45, $1.01 worse than the analyst estimate of $5.46. Revenue for the quarter came in at $1.712 billion versus the consensus estimate of $1.76 billion.
First quarter 2019 GAAP diluted EPS was $3.99 and non-GAAP diluted EPS was $4.45First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018First quarter 2019 EYLEA® (aflibercept) Injection U.S. net sales increased 9% to $1.07 billion versus first quarter 2018First quarter 2019 EYLEA net sales outside the United States, which are recorded by the Company\'s collaborator Bayer(1), increased 7% to $669 million versus... More